Using existing data to identify candidate items for a health state classification system in multiple sclerosis
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
In multiple sclerosis (MS), the use of preference-based measures is limited to generic measures such as Health Utilities Index Mark 2 and 3, the EQ-5D and the SF-6D. However, the challenge of using such generic preference-based measures in people with MS is that they may not capture all domains of health relevant to the disease. Therefore, the main aim of this paper is to describe the development of a health state classification system for MS patients. The specific objectives are: (1) to identify items best reflecting the domains of quality of life important to people with MS and (2) to provide evidence for the discriminative capacity of the response options by cross-walking onto a visual analog scale of health rating.
The data come from an epidemiologically sampled population of people with MS diagnosed post-1994. The dataset consisted of 206 items relating to impairments, activity limitations, participation restrictions, health perception and quality of life. Important domains were identified from the responses to the Patient Generated Index, an individualized measure of quality of life. The extent to which the items formed a uni-dimensional, linear construct was estimated using Rasch analysis, and the best item was selected using the threshold map.
The sample was young (mean age 43) and predominantly female (n = 140/189; 74 %). The P-PBMSI classification system consisted of five items, with three response levels per item, producing a total of 243 possible health states. Regression coefficient values consistently decreased between response levels and the linear test for trend were statistically significant for all items. The linear test for trend indicated that for each item the response options provided the same discriminative ability within the magnitude of their capacity. A scoring algorithm was estimated using a simple additive formula. The classification system demonstrated convergent validity against other measures of similar constructs and known-groups validity between different clinical subgroups.
This study produced a health state classifier system based on items impacted upon by MS, and demonstrated the potential to discriminate the health impact of the disease.
- Miller, D. M., Moore, S. M., Fox, R. J., Atreja, A., Fu, A. Z., Lee, J. C., et al. (2011). Web-based self-management for patients with multiple sclerosis: A practical, randomized trial. Telemedicine Journal & E-Health, 17, 5–13. CrossRef
- Barlow, J., Turner, A., Edwards, R., & Gilchrist, M. (2009). A randomised controlled trial of lay-led self-management for people with multiple sclerosis. Patient Education and Counseling, 77, 81–89. CrossRef
- Bombardier, C. H., Cunniffe, M., Wadhwani, R., Gibbons, L. E., Blake, K. D., & Kraft, G. H. (2008). The efficacy of telephone counseling for health promotion in people with multiple sclerosis: A randomized controlled trial. Archives of Physical Medicine and Rehabilitation, 89, 1849–1856. CrossRef
- McAuley, E., Motl, R. W., Morris, K. S., Hu, L., Doerksen, S. E., Elavsky, S., et al. (2007). Enhancing physical activity adherence and well-being in multiple sclerosis: A randomised controlled trial. Multiple Sclerosis, 13, 652–659. CrossRef
- Grossman, P., Kappos, L., Gensicke, H., D’Souza, M., Mohr, D. C., Penner, I. K., et al. (2010). MS quality of life, depression, and fatigue improve after mindfulness training: A randomized trial. Neurology, 75, 1141–1149. CrossRef
- Forman, A. C., & Lincoln, N. B. (2010). Evaluation of an adjustment group for people with multiple sclerosis: A pilot randomized controlled trial. Clinical Rehabilitation, 24, 211–221. CrossRef
- Cosio, D., Jin, L., Siddique, J., & Mohr, D. C. (2011). The effect of telephone-administered cognitive-behavioral therapy on quality of life among patients with multiple sclerosis. Annals of Behavioral Medicine, 41, 227–234. CrossRef
- Kavia, R. B., De, R. D., Constantinescu, C. S., Stott, C. G., & Fowler, C. J. (2010). Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Multiple Sclerosis, 16, 1349–1359. CrossRef
- Moller, F., Poettgen, J., Broemel, F., Neuhaus, A., Daumer, M., & Heesen, C. (2011). HAGIL (Hamburg Vigil Study): A randomized placebo-controlled double-blind study with modafinil for treatment of fatigue in patients with multiple sclerosis. Multiple Sclerosis, 17, 1002–1009. CrossRef
- Freeman, J. A., Thompson, A. J., Fitzpatrick, R., Hutchinson, M., Miltenburger, C., Beckmann, K., et al. (2001). European Study Group on Interferon-beta: Interferon-beta1b in the treatment of secondary progressive MS: Impact on quality of life. Neurology, 57, 1870–1875. CrossRef
- Rudick, R. A., Miller, D., Hass, S., Hutchinson, M., Calabresi, P. A., Confavreux, C., et al. (2007). AFFIRM and SENTINEL investigators: Health-related quality of life in multiple sclerosis: Effects of natalizumab. Annals of Neurology, 62, 335–346. CrossRef
- Fox, R. J., Miller, D. H., Phillips, J. T., Hutchinson, M., Havrdova, E., Kita, M., et al. (2012). Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. New England Journal of Medicine, 367, 1087–1097. CrossRef
- Freedman, M. S., Bar-Or, A., Atkins, H. L., Karussis, D., Frassoni, F., Lazarus, H., et al. (2010). The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: Consensus report of the International MSCT Study Group. Multiple Sclerosis, 16, 503–510. CrossRef
- Zamboni, P., Menegatti, E., Galeotti, R., Malagoni, A. M., Tacconi, G., Dall’Ara, S., et al. (2009). The value of cerebral Doppler venous haemodynamics in the assessment of multiple sclerosis. Journal of the Neurological Sciences, 282, 21–27. CrossRef
- Al-Omari, M. H., & Rousan, L. A. (2010). Internal jugular vein morphology and hemodynamics in patients with multiple sclerosis. International Angiology, 29, 115–120.
- Baracchini, C., Perini, P., Calabrese, M., Causin, F., Rinaldi, F., & Gallo, P. (2011). No evidence of chronic cerebrospinal venous insufficiency at multiple sclerosis onset. Annals of Neurology, 69, 90–99. CrossRef
- Centonze, D., Floris, R., Stefanini, M., Rossi, S., Fabiano, S., Castelli, M., et al. (2011). Proposed chronic cerebrospinal venous insufficiency criteria do not predict multiple sclerosis risk or severity. Annals of Neurology, 70, 51–58. CrossRef
- Zivadinov, R., Marr, K., Cutter, G., Ramanathan, M., Benedict, R. H., Kennedy, C., et al. (2011). Prevalence, sensitivity, and specificity of chronic cerebrospinal venous insufficiency in MS. Neurology, 77, 138–144. CrossRef
- Feeny, D., Furlong, W., Torrance, G. W., Goldsmith, C. H., Zhu, Z., DePauw, S., et al. (2002). Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Medical Care, 40, 113–128. CrossRef
- Torrance, G. W. (1986). Measurement of health state utilities for economic appraisal. J Health Economics, 5, 1–30. CrossRef
- Torrance, G. W., Boyle, M. H., & Horwood, S. P. (1982). Application of multi-attribute utility theory to measure social preferences for health states. Operations Research, 30, 1043–1069. CrossRef
- Brazier, J., Ratcliffe, J., Salomon, J. A., & Tsuchiya, A. (2007). Measuring and valuing health benefits for economic evaluation. New York: Oxford University Press Inc.
- Mavranezouli, I., Brazier, J. E., Young, T. A., & Barkham, M. (2011). Using Rasch analysis to form plausible health states amenable to valuation: The development of CORE-6D from a measure of common mental health problems (CORE-OM). Quality of Life Research, 20, 321–333. CrossRef
- Kind, P. (2005). Values and valuation in the measurement of HRQoL. In P. Fayers & D. Hays (Eds.), Assessing quality of life in clinical trials (pp. 391–404). New York: Oxford University Press Inc.
- Feeny, D., Torrance, G. W., & Furlong, W. (1996). Health utilities index. In B. Spilker (Ed.), Quality of life and pharmaeconomics in clinicals trials (pp. 239–252). Philadelphia: Lippincott-Raven Publishers.
- Feeny, D. (2005). Preference-based measures: Utility and quality-adjusted life years. In P. Fayers & D. Hays (Eds.), Assessing quality of life in clinical trials (pp. 405–429). New York: Oxford University Press Inc.
- Guyatt, G. H., Feeny, D. H., & Patrick, D. L. (1993). Measuring health-related quality of life. Annals of Internal Medicine, 118, 622–629. CrossRef
- Revicki, D. A., & Kaplan, R. M. (1993). Relationship between psychometric and utility-based approaches to the measurement of health-related quality of life. Quality of Life Research, 2, 477–487. CrossRef
- Berzon, R., Mauskopf, J. A., & Simeon, G. P. (1996). Choosing a health profile (descriptive) and/or a patient-preference (utility) measure for a clinical trial. In B. Spilker (Ed.), Quality of life and pharmaeconomics in clinical trials (pp. 375–379). Philadelphia: Lippincott-Raven Publishers.
- Feeny, D. H., & Torrance, G. W. (1989). Incorporating utility-based quality-of-life assessment measures in clinical trials. Two examples. Medical Care, 27, S190–S204. CrossRef
- Torrance, G. W. (1987). Utility approach to measuring health-related quality of life. Journal of Chronic Diseases, 40, 593–603. CrossRef
- Kind, P., Lafata, J. E., Matuszewski, K., & Raisch, D. (2009). The use of QALYs in clinical and patient decision-making: Issues and prospects. Value Health, 12(Suppl 1), S27–S30. CrossRef
- Hawthorne, G., & Richardson, J. (2001). Measuring the value of program outcomes: A review of multiattribute utility measures. Expert Review of Pharmacoeconomics & Outcomes Research, 1, 215–228. CrossRef
- Guyatt, G. H., Veldhuyzen Van Zanten, S. J., Feeny, D. H., & Patrick, D. L. (1989). Measuring quality of life in clinical trials: A taxonomy and review. Canadian Medical Association Journal, 140, 1441–1448.
- Kuspinar, A., & Mayo, N. E. (2013). Do generic utility measures capture what is important to the quality of life of people with multiple sclerosis? Health and Quality of Life Outcomes, 11, 71. CrossRef
- Hemmett, L., Holmes, J., Barnes, M., & Russell, N. (2004). What drives quality of life in multiple sclerosis? QJM, 97, 671–676. CrossRef
- Nicholl, C. R., Lincoln, N. B., Francis, V. M., & Stephan, T. F. (2001). Assessing quality of life in people with multiple sclerosis. Disability and Rehabilitation, 23, 597–603. CrossRef
- Fisk, J. D., Brown, M. G., Sketris, I. S., Metz, L. M., Murray, T. J., & Stadnyk, K. J. (2005). A comparison of health utility measures for the evaluation of multiple sclerosis treatments. Journal of Neurology, Neurosurgery and Psychiatry, 76, 58–63. CrossRef
- Williams, A. (2005). The EuroQol instrument. In P. Kind, R. Brooks, & R. Rabin (Eds.), EQ-5D concepts and methods: A developmental history (pp. 1–17). Dordrecht: Springers. CrossRef
- Poissant, L., Mayo, N. E., Wood-Dauphinee, S., & Clarke, A. E. (2003). The development and preliminary validation of a Preference-Based Stroke Index (PBSI). Health and Quality of Life Outcomes, 1, 43. CrossRef
- Pickard, A. S., Shaw, J. W., Lin, H. W., Trask, P. C., Aaronson, N., Lee, T. A., et al. (2009). A patient-based utility measure of health for clinical trials of cancer therapy based on the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire. Value Health, 12, 977–988. CrossRef
- Rowen, D., Brazier, J., Young, T., Gaugris, S., Craig, B. M., King, M. T., et al. (2011). Deriving a preference-based measure for cancer using the EORTC QLQ-C30. Value Health, 14, 721–731. CrossRef
- Melsop, K. A., Boothroyd, D. B., & Hlatky, M. A. (2003). Quality of life and time trade-off utility measures in patients with coronary artery disease. American Heart Journal, 145, 36–41. CrossRef
- McKenna, S. P., Ratcliffe, J., Meads, D. M., & Brazier, J. E. (2008). Development and validation of a preference based measure derived from the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for use in cost utility analyses. Health and Quality of Life Outcomes, 6, 65. CrossRef
- Revicki, D. A., Leidy, N. K., Brennan-Diemer, F., Sorensen, S., & Togias, A. (1998). Integrating patient preferences into health outcomes assessment: The multiattribute Asthma Symptom Utility Index. Chest, 114, 998–1007. CrossRef
- Revicki, D. A., Leidy, N. K., Brennan-Diemer, F., Thompson, C., & Togias, A. (1998). Development and preliminary validation of the multiattribute Rhinitis Symptom Utility Index. Quality of Life Research, 7, 693–702. CrossRef
- Brazier, J., Czoski-Murray, C., Roberts, J., Brown, M., Symonds, T., & Kelleher, C. (2008). Estimation of a preference-based index from a condition-specific measure: The King’s Health Questionnaire. Medical Decision Making, 28, 113–126. CrossRef
- Torrance, G. W., Keresteci, M. A., Casey, R. W., Rosner, A. J., Ryan, N., & Breton, M. C. (2004). Development and initial validation of a new preference-based disease-specific health-related quality of life instrument for erectile function. Quality of Life Research, 13, 349–359. CrossRef
- Guyatt, G. H., Bombardier, C., & Tugwell, P. X. (1986). Measuring disease-specific quality of life in clinical trials. Canadian Medical Association Journal, 134, 889–895.
- Brazier, J., & Fitzpatrick, R. (2002). Measures of health-related quality of life in an imperfect world: A comment on Dowie. Health Economics, 11, 17–19. CrossRef
- Patrick, D. L., Burke, L. B., Powers, J. H., Scott, J. A., Rock, E. P., Dawisha, S., et al. (2007). Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health, 10(Suppl 2), S125–S137. CrossRef
- Lin, F. J., Longworth, L., Pickard, A. S. (2013). Evaluation of content on EQ-5D as compared to disease-specific utility measures. Quality Life Research, 22(4), 853–874.
- Mayo, N. (2008). Setting the agenda for multiple sclerosis rehabilitation research. Multiple Sclerosis, 14, 1154–1156. CrossRef
- Freeman, J. A., Hobart, J. C., Langdon, D. W., & Thompson, A. J. (2000). Clinical appropriateness: A key factor in outcome measure selection: The 36 item short form health survey in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 68, 150–156. CrossRef
- Nortvedt, M. W., Riise, T., Myhr, K. M., & Nyland, H. I. (2000). Performance of the SF-36, SF-12, and RAND-36 summary scales in a multiple sclerosis population. Medical Care, 38, 1022–1028. CrossRef
- Kikuchi, H., Mifune, N., Niino, M., Ohbu, S., Kira, J., Kohriyama, T., et al. (2011). Impact and characteristics of quality of life in Japanese patients with multiple sclerosis. Quality of Life Research, 20, 119–131. CrossRef
- Twiss, J., Doward, L. C., McKenna, S. P., & Eckert, B. (2010). Interpreting scores on multiple sclerosis-specific patient reported outcome measures (the PRIMUS and U-FIS). Health and Quality of Life Outcomes, 8, 117. CrossRef
- Ruta, D. A., Garratt, A. M., & Russell, I. T. (1999). Patient centred assessment of quality of life for patients with four common conditions. Quality Health Care, 8, 22–29. CrossRef
- Sullivan, M. J., Edgley, K., & Dehoux, E. (1990). A survey of multiple sclerosis: I. Perceived cognitive problems and compensatory strategy use. Canadian Journal of Rehabilitation, 4, 99–105.
- Marrie, R. A., Miller, D. M., Chelune, G. J., & Cohen, J. A. (2003). Validity and reliability of the MSQLI in cognitively impaired patients with multiple sclerosis. Multiple Sclerosis, 9, 621–626. CrossRef
- Paltamaa, J., West, H., Sarasoja, T., Wikstrom, J., & Malkia, E. (2005). Reliability of physical functioning measures in ambulatory subjects with MS. Physiotherapy Research International, 10, 93–109. CrossRef
- Kurtzke, J. F. (1983). Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology, 33, 1444–1452. CrossRef
- Ruta, D. A., Garratt, A. M., Leng, M., Russell, I. T., & MacDonald, L. M. (1994). A new approach to the measurement of quality of life. The Patient-Generated Index. Medical Care, 32, 1109–1126. CrossRef
- Schumacker, R. E. (1996). Editor’s note. Structural Equation Modeling: A Multidisciplinary Journal, 3, 1–2. CrossRef
- Wright, B. D. (1996). Comparing Rasch measurement and factor analysis. Structural Equation Modeling: A Multidisciplinary Journal, 3, 3–24. CrossRef
- Chang, C. H. (1996). Finding two dimensions in MMPI-2 depression. Structural Equation Modeling: A Multidisciplinary Journal, 3, 41–49. CrossRef
- Young, T., Yang, Y., Brazier, J. E., Tsuchiya, A., & Coyne, K. (2009). The first stage of developing preference-based measures: constructing a health-state classification using Rasch analysis. Quality of Life Research, 18, 253–265. CrossRef
- Andrich, D., Lyne, A., Sheridan, B., & Luo, G. (2004). Rasch unidimensional measurement models (RUMM) 2020. Perth, Western Australia: Rumm Laboratory Pty Ltd.
- Pallant, J. F., & Tennant, A. (2007). An introduction to the Rasch measurement model: An example using the Hospital Anxiety and Depression Scale (HADS). British Journal of Clinical Psychology, 46, 1–18. CrossRef
- Gibbons, C. J., Mills, R. J., Thornton, E. W., Ealing, J., Mitchell, J. D., Shaw, P. J., et al. (2011). Rasch analysis of the hospital anxiety and depression scale (HADS) for use in motor neurone disease. Health and Quality of Life Outcomes, 9, 82. CrossRef
- Bond, T. G., & Fox, C. M. (2007). Applying the Rasch model: Fundamental measurement in the human science. New Jersey: Lawrence Erlbaum Associates Inc.
- Allen, M. J., & Yen, W. M. (2002). Introduction to measurement theory. Long Grove: Waveland Press Inc.
- Cohen, J. (1992). A power primer. Psychological Bulletin, 112, 155–159. CrossRef
- Broome, H. (2012) The association between cognition, social functioning, physical impairment, and relationship factors in individuals with multiple sclerosis (pp. 1–195). The University of Hull.
- Mead, D. E. (2002). Marital distress, co-occurring depression, and marital therapy: A review. Journal of Marital and Family Therapy, 28, 299–314. CrossRef
- Lee, E. K. O., & Oh, H. (2012). Marital satisfaction among adults with disabilities in South Korea. Journal of Disability Studies Policy, 23, 215–224. CrossRef
- Mayo, N. E., Hum, S., & Kuspinar, A. (2013). Methods and measures: What’s new for MS? Multiple Sclerosis, 19, 709–713. CrossRef
- Krupp, L. B., & Pollina, D. A. (1996). Mechanisms and management of fatigue in progressive neurological disorders. Current Opinion in Neurology, 9, 456–460. CrossRef
- Fisk, J. D., Pontefract, A., Ritvo, P. G., Archibald, C. J., & Murray, T. J. (1994). The impact of fatigue on patients with multiple sclerosis. Canadian Journal of Neurological Sciences, 21, 9–14.
- Freal, J. E., Kraft, G. H., & Coryell, J. K. (1984). Symptomatic fatigue in multiple sclerosis. Archives of Physical Medicine and Rehabilitation, 65, 135–138.
- Murray, T. J. (1985). Amantadine therapy for fatigue in multiple sclerosis. Canadian Journal of Neurological Sciences, 12, 251–254.
- Deloire, M. S., Bonnet, M. C., Salort, E., Arimone, Y., Boudineau, M., Petry, K. G., et al. (2006). How to detect cognitive dysfunction at early stages of multiple sclerosis? Multiple Sclerosis, 12, 445–452. CrossRef
- Peyser, J. M., Edwards, K. R., Poser, C. M., & Filskov, S. B. (1980). Cognitive function in patients with multiple sclerosis. Archives of Neurology, 37, 577–579. CrossRef
- Brazier, J., Akehurst, R., Brennan, A., Dolan, P., Claxton, K., McCabe, C., et al. (2005). Should patients have a greater role in valuing health states? Applied Health Economics and Health Policy, 4, 201–208. CrossRef
- Ubel, P. A., Loewenstein, G., & Jepson, C. (2003). Whose quality of life? A commentary exploring discrepancies between health state evaluations of patients and the general public. Quality of Life Research, 12, 599–607. CrossRef
- Whitehead, S. J., & Ali, S. (2010). Health outcomes in economic evaluation: The QALY and utilities. British Medical Bulletin, 96, 5–21. CrossRef
- Stallard, J., & Major, R. E. (1995). The influence of orthosis stiffness on paraplegic ambulation and its implications for functional electrical stimulation (FES) walking systems. Prosthetics and Orthotics International, 19, 108–114.
- Brissot, R., Gallien, P., Le Bot, M. P., Beaubras, A., Laisne, D., Beillot, J., et al. (2000). Clinical experience with functional electrical stimulation-assisted gait with Parastep in spinal cord-injured patients. Spine (Phila Pa 1976), 25, 501–508. CrossRef
- Thoumie, P., Perrouin-Verbe, B., Le, C. G., Bedoiseau, M., Busnel, M., Cormerais, A., et al. (1995). Restoration of functional gait in paraplegic patients with the RGO-II hybrid orthosis. A multicentre controlled study. I. Clinical evaluation. Paraplegia, 33, 647–653. CrossRef
- Rothman, M., Burke, L., Erickson, P., Leidy, N. K., Patrick, D. L., & Petrie, C. D. (2009). Use of existing patient-reported outcome (PRO) instruments and their modification: The ISPOR good research practices for evaluating and documenting content validity for the use of existing instruments and their modification PRO task force report. Value Health, 12, 1075–1083. CrossRef
- Food, U. S. (2009). Drug administration: Guidance for industry: Patient-reported outcome measures: Use in medical product development to support labeling claims. Federal Register, 74, 65132–65133.
- Using existing data to identify candidate items for a health state classification system in multiple sclerosis
Quality of Life Research
Volume 23, Issue 5 , pp 1445-1457
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Health-related quality of life
- Preference-based measures
- Multiple sclerosis
- Industry Sectors
- Author Affiliations
- 1. Faculty of Medicine, School of Physical and Occupational Therapy, McGill University, 3654 Prom Sir William Osler, Montreal, QC, H3G 1Y5, Canada
- 2. Division of Clinical Epidemiology, McGill University Health Center, Montreal, QC, Canada
- 3. Department of Pharmacy Systems, Outcomes and Policy, Center for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago, Chicago, IL, USA